156 related articles for article (PubMed ID: 31121994)
21. 5α-Reductase Inhibitors and Risk of Kidney and Bladder Cancers in Men with Benign Prostatic Hyperplasia: A Population-Based Cohort Study.
Doherty N; Cardwell CR; Murchie P; Hill C; Azoulay L; Hicks B
Cancer Epidemiol Biomarkers Prev; 2023 Mar; 32(3):428-434. PubMed ID: 36634196
[TBL] [Abstract][Full Text] [Related]
22. Impact of Benign Prostatic Hyperplasia and/or Prostatitis on the Risk of Prostate Cancer in Korean Patients.
Kim SH; Kwon WA; Joung JY
World J Mens Health; 2021 Apr; 39(2):358-365. PubMed ID: 32202082
[TBL] [Abstract][Full Text] [Related]
23. Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?
Cindolo L; Pirozzi L; Sountoulides P; Fanizza C; Romero M; Castellan P; Antonelli A; Simeone C; Tubaro A; de Nunzio C; Schips L
BMC Urol; 2015 Sep; 15():96. PubMed ID: 26391357
[TBL] [Abstract][Full Text] [Related]
24. Incontinence related to management of benign prostatic hypertrophy.
Han E; Black LK; Lavelle JP
Am J Geriatr Pharmacother; 2007 Dec; 5(4):324-34. PubMed ID: 18179990
[TBL] [Abstract][Full Text] [Related]
25. Benign prostatic hyperplasia and cardiovascular risk: a prospective study among Chinese men.
Wang X; Su Y; Yang C; Hu Y; Dong JY
World J Urol; 2022 Jan; 40(1):177-183. PubMed ID: 34426873
[TBL] [Abstract][Full Text] [Related]
26. Benign Prostatic Hyperplasia and Incident Cardiovascular Disease.
Suzuki Y; Kaneko H; Okada A; Fujiu K; Jo T; Takeda N; Tanaka A; Node K; Morita H; Yasunaga H; Komuro I
Circ J; 2024 Feb; 88(3):408-416. PubMed ID: 38246651
[TBL] [Abstract][Full Text] [Related]
27. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride.
Issa MM; Runken MC; Grogg AL; Shah MB
Am J Manag Care; 2007 Feb; 13 Suppl 1():S10-6. PubMed ID: 17295600
[TBL] [Abstract][Full Text] [Related]
28. Increased One-Year Recurrent Ischemic Stroke after First-Ever Ischemic Stroke in Males with Benign Prostatic Hyperplasia.
Cheng CG; Chu H; Lee JT; Chien WC; Cheng CA
Int J Environ Res Public Health; 2020 Jul; 17(15):. PubMed ID: 32722374
[TBL] [Abstract][Full Text] [Related]
29. Association of Blood Pressure Classification in Korean Young Adults According to the 2017 American College of Cardiology/American Heart Association Guidelines With Subsequent Cardiovascular Disease Events.
Son JS; Choi S; Kim K; Kim SM; Choi D; Lee G; Jeong SM; Park SY; Kim YY; Yun JM; Park SM
JAMA; 2018 Nov; 320(17):1783-1792. PubMed ID: 30398603
[TBL] [Abstract][Full Text] [Related]
30. Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men--a randomized multicenter study.
Lin VC; Liao CH; Kuo HC
Urology; 2014 Feb; 83(2):416-21. PubMed ID: 24332123
[TBL] [Abstract][Full Text] [Related]
31. Association of antipsychotics adherence and cardiovascular disease among newly diagnosed schizophrenia patients: A national cohort among Koreans.
Chang J; Kim JA; Kim K; Choi S; Kim SM; Nam YY; Park S; Goo AJ; Park SM
Asian J Psychiatr; 2020 Aug; 52():102161. PubMed ID: 32454424
[TBL] [Abstract][Full Text] [Related]
32. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
[TBL] [Abstract][Full Text] [Related]
33. α-Blocker and Risk of Dementia in Patients with Benign Prostatic Hyperplasia: A Nationwide Population Based Study Using the National Health Insurance Service Database.
Tae BS; Jeon BJ; Choi H; Cheon J; Park JY; Bae JH
J Urol; 2019 Aug; 202(2):362-368. PubMed ID: 30840545
[TBL] [Abstract][Full Text] [Related]
34. 5-alpha-reductase inhibitor therapy postpones urine retention and prostate surgery in patients with prostate enlargement and a maximum uroflow rate of less than 15 ml/sec.
Lin W; Lee S; Wu J; Kuo Y; Hsieh T
PLoS One; 2017; 12(4):e0175356. PubMed ID: 28394903
[TBL] [Abstract][Full Text] [Related]
35. Hyperthyroidism is not a significant risk of benign prostatic hyperplasia: A nationwide population-based study.
Man KM; Chen KB; Chen HY; Chiang JH; Su YC; Man SS; Xie DD; Wang Y; Zhang ZQ; Bi LK; Zhang T; Yu DX; Chen WC
Medicine (Baltimore); 2018 Sep; 97(39):e12459. PubMed ID: 30278528
[TBL] [Abstract][Full Text] [Related]
36. 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia.
Chou CH; Lin CL; Lin MC; Sung FC; Kao CH
J Endocrinol Invest; 2015 Jul; 38(7):799-805. PubMed ID: 25778849
[TBL] [Abstract][Full Text] [Related]
37. Increased Risk of Benign Prostate Hyperplasia (BPH) in Patients with Gout: A Longitudinal Follow-Up Study Using a National Health Screening Cohort.
Bang WJ; Choi HG; Kang HS; Kwon MJ; Kim JH; Kim JH; Kim SY
Diagnostics (Basel); 2023 Dec; 14(1):. PubMed ID: 38201364
[TBL] [Abstract][Full Text] [Related]
38. Five-alpha-reductase Inhibitors for prostate cancer prevention.
Wilt TJ; MacDonald R; Hagerty K; Schellhammer P; Kramer BS
Cochrane Database Syst Rev; 2008 Apr; (2):CD007091. PubMed ID: 18425978
[TBL] [Abstract][Full Text] [Related]
39. Association of benign prostatic hyperplasia and subsequent risk of bladder cancer: an Asian population cohort study.
Fang CW; Liao CH; Wu SC; Muo CH
World J Urol; 2018 Jun; 36(6):931-938. PubMed ID: 29427001
[TBL] [Abstract][Full Text] [Related]
40. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia.
Duan Y; Grady JJ; Albertsen PC; Helen Wu Z
Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):340-348. PubMed ID: 29316005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
